Equities Analysts Set Expectations for MREO Q1 Earnings

Mereo BioPharma Group plc (NASDAQ:MREO) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Mereo BioPharma Group in a note issued to investors on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz expects that the company will post earnings per share of $0.07 for the quarter. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Mereo BioPharma Group’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at $0.08 EPS and FY2026 earnings at ($0.03) EPS.

Mereo BioPharma Group (NASDAQ:MREO) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.03).

A number of other brokerages have also commented on MREO. Lifesci Capital started coverage on shares of Mereo BioPharma Group in a report on Tuesday, December 24th. They issued an “outperform” rating and a $10.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on Mereo BioPharma Group in a research note on Thursday, March 27th. They issued an “overweight” rating and a $7.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research note on Wednesday, March 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a report on Tuesday, March 18th. Finally, Jefferies Financial Group started coverage on Mereo BioPharma Group in a report on Friday, December 6th. They set a “buy” rating and a $7.00 price objective on the stock. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $7.71.

Mereo BioPharma Group Price Performance

Shares of MREO opened at $2.17 on Monday. Mereo BioPharma Group has a 1-year low of $2.11 and a 1-year high of $5.02. The company has a market capitalization of $336.67 million, a P/E ratio of -36.17 and a beta of 1.03. The firm’s 50 day simple moving average is $2.69 and its 200 day simple moving average is $3.45.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Fred Alger Management LLC grew its position in Mereo BioPharma Group by 108.1% during the 3rd quarter. Fred Alger Management LLC now owns 102,582 shares of the company’s stock worth $422,000 after acquiring an additional 53,278 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Mereo BioPharma Group by 56.7% in the third quarter. Janus Henderson Group PLC now owns 12,345,866 shares of the company’s stock worth $50,865,000 after purchasing an additional 4,464,984 shares during the last quarter. Polar Asset Management Partners Inc. increased its stake in shares of Mereo BioPharma Group by 36.0% in the third quarter. Polar Asset Management Partners Inc. now owns 198,300 shares of the company’s stock worth $815,000 after buying an additional 52,500 shares during the period. State Street Corp bought a new stake in Mereo BioPharma Group during the 3rd quarter valued at $195,000. Finally, Frazier Life Sciences Management L.P. boosted its position in Mereo BioPharma Group by 15.8% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 5,097,779 shares of the company’s stock valued at $20,952,000 after buying an additional 696,408 shares during the period. Hedge funds and other institutional investors own 62.83% of the company’s stock.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.